THIRD Amendment to License, Collaboration, and Option AgreementLicense, Collaboration, and Option Agreement • August 4th, 2021 • Sarepta Therapeutics, Inc. • Pharmaceutical preparations • New York
This THIRD AMENDMENT TO LICENSE, COLLABORATION, AND OPTION AGREEMENT (this “Third Amendment”) is made and entered into as of February 4, 2021 (the “Third Amendment Effective Date”) between Sarepta Therapeutics Three LLC, a limited liability company organized and existing under the laws of the State of Delaware, United States of America, with its principal offices at 215 First Street, Cambridge, MA, 02142 (“Sarepta”) and F. Hoffmann-La Roche Ltd, a company organized and existing under the laws of Switzerland, with its principal office at Grenzacherstrasse 124, 4070 Basel, Switzerland (“Roche”). Sarepta and Roche may be referred to herein individually as a “Party” and collectively as the “Parties.”
EIGHTH AMENDMENT TO LICENSE, COLLABORATION, AND OPTION AGREEMENTLicense, Collaboration, and Option Agreement • March 1st, 2022 • Sarepta Therapeutics, Inc. • Pharmaceutical preparations • New York
WHEREAS, Sarepta and Roche entered into that certain License, Collaboration, and Option Agreement executed on December 21, 2019 and effective as of February 4, 2020 and amended October 23, 2020,
THIRTEENTH AMENDMENT TO LICENSE, COLLABORATION, AND OPTION AGREEMENT This THIRTEENTH AMENDMENT TO LICENSE, COLLABORATION, AND OPTION AGREEMENTLicense, Collaboration, and Option Agreement • February 28th, 2024 • Sarepta Therapeutics, Inc. • Pharmaceutical preparations • New York
WHEREAS, Sarepta and Roche entered into that certain License, Collaboration, and Option Agreement executed on December 21, 2019 and effective as of February 4, 2020 and amended October 23, 2020,
ELEVENTH AMENDMENT TO LICENSE, COLLABORATION, AND OPTION AGREEMENT This ELEVENTH AMENDMENT TO LICENSE, COLLABORATION, AND OPTION AGREEMENT (this “Eleventh Amendment”) is made and entered into as of June 23, 2022 (the “Eleventh Amendment Effective...License, Collaboration, and Option Agreement • February 28th, 2024 • Sarepta Therapeutics, Inc. • Pharmaceutical preparations • New York
WHEREAS, Sarepta and Roche entered into that certain License, Collaboration, and Option Agreement executed on December 21, 2019 and effective as of February 4, 2020 and amended October 23, 2020,
SEVENTH AMENDMENT TO LICENSE, COLLABORATION, AND OPTION AGREEMENT This SEVENTH AMENDMENT TO LICENSE, COLLABORATION, AND OPTION AGREEMENTLicense, Collaboration, and Option Agreement • March 1st, 2022 • Sarepta Therapeutics, Inc. • Pharmaceutical preparations • New York
(this “Seventh Amendment”) is made and entered into as of January 5, 2022 (the “Seventh Amendment Effective Date”) between Sarepta Therapeutics Three LLC, a limited liability company organized and existing under the laws of the State of Delaware, United States of America, with its principal offices at 215 First Street, Cambridge, MA, 02142 (“Sarepta”) and F. Hoffmann-La Roche Ltd, a company organized and existing under the laws of Switzerland, with its principal office at Grenzacherstrasse 124, 4070 Basel, Switzerland (“Roche”). Sarepta and Roche may be referred to herein individually as a “Party” and collectively as the “Parties.”
FOURTEENTH AMENDMENT TO LICENSE, COLLABORATION, AND OPTION AGREEMENT This FOURTEENTH AMENDMENT TO LICENSE, COLLABORATION, AND OPTIONLicense, Collaboration, and Option Agreement • February 28th, 2024 • Sarepta Therapeutics, Inc. • Pharmaceutical preparations • New York
WHEREAS, Sarepta and Roche entered into that certain License, Collaboration, and Option Agreement executed on December 21, 2019 and effective as of February 4, 2020 and amended October 23, 2020,
SECOND Amendment to License, Collaboration, and Option AgreementLicense, Collaboration, and Option Agreement • August 4th, 2021 • Sarepta Therapeutics, Inc. • Pharmaceutical preparations • New York
This SECOND AMENDMENT TO LICENSE, COLLABORATION, AND OPTION AGREEMENT (this “Second Amendment”) is made and entered into as of October 28, 2020 (the “Second Amendment Effective Date”) between Sarepta Therapeutics Three LLC, a limited liability company organized and existing under the laws of the State of Delaware, United States of America, with its principal offices at 215 First Street, Cambridge, MA, 02142 (“Sarepta”) and F. Hoffmann-La Roche Ltd, a company organized and existing under the laws of Switzerland, with its principal office at Grenzacherstrasse 124, 4070 Basel, Switzerland (“Roche”). Sarepta and Roche may be referred to herein individually as a “Party” and collectively as the “Parties.”
NINTH Amendment to License, Collaboration, and Option AgreementLicense, Collaboration, and Option Agreement • August 2nd, 2022 • Sarepta Therapeutics, Inc. • Pharmaceutical preparations • New York
This NINTH AMENDMENT TO LICENSE, COLLABORATION, AND OPTION AGREEMENT (this “Ninth Amendment”) is made and entered into as of March 23, 2022 (the “Ninth Amendment Effective Date”) between Sarepta Therapeutics Three LLC, a limited liability company organized and existing under the laws of the State of Delaware, United States of America, with its principal offices at 215 First Street, Cambridge, MA, 02142 (“Sarepta”) and F. Hoffmann-La Roche Ltd, a company organized and existing under the laws of Switzerland, with its principal office at Grenzacherstrasse 124, 4070 Basel, Switzerland (“Roche”). Sarepta and Roche may be referred to herein individually as a “Party” and collectively as the “Parties.”
TWELFTH AMENDMENT TO LICENSE, COLLABORATION, AND OPTION AGREEMENT This TWELFTH AMENDMENT TO LICENSE, COLLABORATION, AND OPTION AGREEMENT (this “Twelfth Amendment”) is made and entered into as of July 28, 2022 (the “Twelfth Amendment Effective Date”)...License, Collaboration, and Option Agreement • February 28th, 2024 • Sarepta Therapeutics, Inc. • Pharmaceutical preparations • New York
WHEREAS, Sarepta and Roche entered into that certain License, Collaboration, and Option Agreement executed on December 21, 2019 and effective as of February 4, 2020 and amended October 23, 2020,
TENTH AMENDMENT TO LICENSE, COLLABORATION, AND OPTION AGREEMENTLicense, Collaboration, and Option Agreement • February 28th, 2023 • Sarepta Therapeutics, Inc. • Pharmaceutical preparations • New York
WHEREAS, Sarepta and Roche entered into that certain License, Collaboration, and Option Agreement executed on December 21, 2019 and effective as of February 4, 2020 and amended October 23, 2020,
FOURTH Amendment to License, Collaboration, and Option AgreementLicense, Collaboration, and Option Agreement • August 4th, 2021 • Sarepta Therapeutics, Inc. • Pharmaceutical preparations • New York
This FOURTH AMENDMENT TO LICENSE, COLLABORATION, AND OPTION AGREEMENT (this “Fourth Amendment”) is made and entered into as of June 23, 2021 (the “Fourth Amendment Effective Date”) between Sarepta Therapeutics Three LLC, a limited liability company organized and existing under the laws of the State of Delaware, United States of America, with its principal offices at 215 First Street, Cambridge, MA, 02142 (“Sarepta”) and F. Hoffmann-La Roche Ltd, a company organized and existing under the laws of Switzerland, with its principal office at Grenzacherstrasse 124, 4070 Basel, Switzerland (“Roche”). Sarepta and Roche may be referred to herein individually as a “Party” and collectively as the “Parties.”
FIRST Amendment to License, Collaboration, and Option AgreementLicense, Collaboration, and Option Agreement • August 4th, 2021 • Sarepta Therapeutics, Inc. • Pharmaceutical preparations • New York
This FIRST AMENDMENT TO LICENSE, COLLABORATION, AND OPTION AGREEMENT (this “First Amendment”) is made and entered into as of October 23, 2020 (the “First Amendment Effective Date”) between Sarepta Therapeutics Three LLC, a limited liability company organized and existing under the laws of the State of Delaware, United States of America, with its principal offices at 215 First Street, Cambridge, MA, 02142 (“Sarepta”) and F. Hoffmann-La Roche Ltd, a company organized and existing under the laws of Switzerland, with its principal office at Grenzacherstrasse 124, 4070 Basel, Switzerland (“Roche”). Sarepta and Roche may be referred to herein individually as a “Party” and collectively as the “Parties.”
License, Collaboration, and Option AgreementLicense, Collaboration, and Option Agreement • February 26th, 2020 • Sarepta Therapeutics, Inc. • Pharmaceutical preparations • New York
This License, Collaboration, and Option Agreement (this “Agreement”) is made and entered into as of December 21, 2019 (the “Execution Date”) between Sarepta Therapeutics Three LLC, a limited liability company organized and existing under the laws of the State of Delaware, United States of America, with its principal offices at 215 First Street, Cambridge, MA, 02142 (“Sarepta”) and F. Hoffmann-La Roche Ltd, a company organized and existing under the laws of Switzerland, with its principal office at Grenzacherstrasse 124, 4070 Basel, Switzerland (“Roche”).
SIXTH AMENDMENT TO LICENSE, COLLABORATION, AND OPTION AGREEMENTLicense, Collaboration, and Option Agreement • March 1st, 2022 • Sarepta Therapeutics, Inc. • Pharmaceutical preparations • New York
WHEREAS, Sarepta and Roche entered into that certain License, Collaboration, and Option Agreement executed on December 21, 2019 and effective as of February 4, 2020 and amended October 23, 2020,
FIFTH AMENDMENT TO LICENSE, COLLABORATION, AND OPTION AGREEMENTLicense, Collaboration, and Option Agreement • November 3rd, 2021 • Sarepta Therapeutics, Inc. • Pharmaceutical preparations • New York
WHEREAS, Sarepta and Roche entered into that certain License, Collaboration, and Option Agreement executed on December 21, 2019 and effective as of February 4, 2020 and amended October 23, 2020, October 28, 2020, February 4, 2021, and June 23, 2021 (the “Original Agreement”); and WHEREAS, the Parties desire to make certain further amendments to the Original Agreement;
